DOI: 10.5061/dryad.c866t1gdq
title: Data from: Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T-cadherin

description: Pharmacological activation of hypoxia-inducible factor 1alpha (HIF-1α), a
 hypoxia-responsive transcription factor, has attracted increasing
 attention due to its efficacy not only in renal anemia but also in various
 disease models. Our study demonstrated that a HIF-1 activator enhanced
 exosome production from cultured endothelial cells synergistically with
 adiponectin, an adipocyte-derived factor, through both transcriptional
 induction and posttranscriptional stabilization of an adiponectin binding
 partner, T-cadherin. Increased exosome levels were observed in wild-type
 mice but not in T-cadherin null mice after consecutive administration of
 roxadustat. Adiponectin- and T-cadherin-dependent increased exosome
 production may be involved in the pleiotropic effects of HIF-1 activators.
description: # Data from: Pharmacological HIF-1 activation upregulates extracellular
 vesicle production synergistically with adiponectin through
 transcriptional induction and protein stabilization of T-cadherin
 [https://doi.org/10.5061/dryad.c866t1gdq](https://doi.org/10.5061/dryad.c866t1gdq) This README file was generated on 2024-04-09 by Kohei Fujii. GENERAL INFORMATION 1. Title of Dataset: Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T cadherin 2. Author Information A. Corresponding author Contact Information Name: Yuya Fujishima M.D., Ph.D. and Shunbun Kita, Ph.D. Institution: Osaka University Address: 2-2, Yamada-oka, Suita, Osaka, 565-0871, Japan Email: [y.fujishima@endmet.med.osaka-u.ac.jp](mailto:y.fujishima@endmet.med.osaka-u.ac.jp). 3. Date of data collection (single date, range, approximate date): 2017-2023 4. Geographic location of data collection: Japan 5. Information about funding sources that supported the collection of the data: This work was supported in part by Grants-in-Aid for Scientific Research (C) no. 21K16353 (to Y.F.), no. 22K08669 (to S.K.), no. 21K16340 (to S.F.), no. 23K07989 (to N.M.), and no. 23K08006 (to H.N.) Japan Association of Medical Research and Development no. 22712587 (to S.K. and I.S.), MSD Life Science Foundation (to S.F.), Bayer Scholarship for Cardiovascular Research (to Y.F.), Manpei Suzuki Diabetes Foundation (to Y.F.), and Suzuken Memorial Foundation (to Y.F.). The funding agencies had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation. SHARING/ACCESS INFORMATION 1. Licenses/restrictions placed on the data: Attribution 4.0 International License (CC BY 4.0) 2. Links to publications that cite or use the data: Kohei Fujii, Yuya Fujishima, Shunbun Kita, Keitaro Kawada, Keita Fukuoka, Taka-aki Sakaue, Tomonori Okita, Emi Kawada-Horitani, Hirofumi Nagao, Shiro Fukuda, Norikazu Maeda, Hitoshi Nishizawa, and Iichiro Shimomura (2024). Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T cadherin. 3. Links to other publicly accessible locations of the data: None 4. Links/relationships to ancillary data sets: None 5. Was data derived from another source? No A. If yes, list source(s): NA 6. Recommended citation for this dataset: Kohei Fujii, Yuya Fujishima, Shunbun Kita, Keitaro Kawada, Keita Fukuoka, Taka-aki Sakaue, Tomonori Okita, Emi Kawada-Horitani, Hirofumi Nagao, Shiro Fukuda, Norikazu Maeda, Hitoshi Nishizawa, and Iichiro Shimomura (2024). Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T cadherin. Dryad Digital Repository. [https://doi.org/10.5061/dryad.c866t1gdq](https://doi.org/10.5061/dryad.c866t1gdq) ## Description of the data and file structure Data & File flowview 1. File List: * In Image Lab Image Document Folder A) User 2023-03-24 14h44m45s.scn B) User 2023-03-24 14h50m06s.scn C) User 2023-03-24 14h53m14s.scn D) User 2023-03-14 13h16m41s.scn E) User 2023-03-14 13h22m16s.scn F) User 2023-03-14 13h24m53s.scn G) User 2022-02-09 17h31m06s.scn H) User 2022-02-09 17h35m49s.scn I) User 2022-02-09 17h39m26s.scn J) User 2023-06-01 14h02m21s.scn K) User 2023-06-01 14h05m20s.scn L) User 2023-06-01 14h08m22s.scn M) User 2023-07-06 13h58m50s.scn N) User 2023-07-06 14h11m48s.scn O) User 2023-07-06 14h14m54s.scn P) User 2023-07-15 13h27m46s.scn Q) User 2023-07-15 13h31m19s.scn R) User 2023-07-15 13h35m19s.scn S) User 2022-11-24 16h38m04s.scn T) User 2022-11-24 16h43m15s.scn U) User 2022-11-24 16h48m35s.scn V) User 2023-10-12 14h02m05s.scn W) User 2023-10-13 13h40m01s.scn X) User 2023-07-20 13h35m17s.scn Y) User 2023-07-20 13h38m46s.scn Z) User 2023-08-11 13h35m27s.scn AA) User 2023-08-11 13h39m01s.scn AB) User 2023-08-11 13h42m07s.scn AC) User 2023-08-24 11h31m18s.scn AD) User 2023-08-24 15h28m13s.scn AE) User 2023-03-22 13h39m35s.scn AF) User 2023-03-22 13h43m40s.scn AG) User 2023-06-09 15h35m45s.scn AH) User 2023-06-09 15h39m49s.scn AI) User 2023-05-26 16h04m39s.scn AJ) User 2023-05-26 16h09m52s.scn AK) F2_T-cad_2017-07-07 11h53m37s 11.477s.scn AL) F2_Tub_2017-07-07 11h51m34s 13.609s.scn * In TIFF Folder AM) 1E atubulin.tif AN) 1E GAPDH.tif AO) 1E T-cad.tif AP) 1F atubulin.tif AQ) 1F GAPDH.tif AR) 1F T-cad.tif AS) 2A APN.tif AT) 2A atubulin.tif AU) 2A T-cad.tif AV) 2B Alix.tif AW) 2B Syntenin.tif AX) 2B TSG101.tif AY) 2C APN.tif AZ) 2C atubulin.tif BA) 2C T-cad.tif BB) 2D Alix.tif BC) 2D Syntenin.tif BD) 2D TSG101.tif BE) 3B APN.tif BF) 3B atubulin.tif BG) 3B T-cad.tif BH) 3D SYPRO Ruby.tif BI) 3D T-cad.tif BJ) 4G atubulin.tif BK) 4G T-cad.tif BL) 4H Alix.tif BM) 4H Syntenin.tif BN) 4H TSG101.tif BO) S1E atubulin.tif BP) S1E T-cad.tif BQ) S1H atubulin.tif BR) S1H T-cad.tif BS) S2B atubulin.tif BT) S2B T-cad.tif BU) S2C atubulin.tif BV) S2C T-cad.tif BW) S2D atubulin.tif BX) S2D T-cad.tif 1. Relationship between files, if important: .tif files were made from .scn files by using Image Lab software ver. 6.0.1 (Bio-Lad). AM) was made from B), AN) from C), AO) from A), AP) from E), AQ) from F), AR) from D), AS) from I), AT) from H), AU) from G), AV) from J), AW) from L), AX) from K), AY) from O), AZ) from N), BA) from M), BB) from P), BC) from R), BD) from Q), BE) from U), BF) from T), BG) from S), BH) from W), BI) from V), BJ) from Y), BK) from X), BL) from Z), BM) from AB), BN) from AA), BO) from AD), BP) from AC), BQ) from AF), BR) from AE), BS) from AH), BT) from AG), BU) from AJ), BV) from AI), BW) from AL) and BX) from AK). 2. Additional related data collected that was not included in the current data package: None 3. Are there multiple versions of the dataset? No A. If yes, name of file(s) that was updated: NA i. Why was the file updated? NA ii. When was the file updated? NA \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-24 14h44m45s.scn and 1E T-cad.tif Western blot analysis of total cell lysates. UV-F2 cells were treated with roxadustat (Roxa) for 48hrs. Goat polyclonal anti-T-cadherin (Anti-T-cad: AF3264, R&D Systems) was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 50 μM, 4th, 8th, 12th lanes: Roxa 250 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-24 14h50m06s.scn and 1E atubulin.tif Western blot analysis of total cell lysates. UV-F2 cells were treated with roxadustat (Roxa) for 48hrs. Rabbit monoclonal anti-α-tubulin (Anti-α-tubulin: 2125S, Cell Signaling Technology) was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 50 μM, 4th, 8th, 12th lanes: Roxa 250 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-24 14h53m14s.scn and 1E GAPDH.tif Western blot analysis of total cell lysates. UV-F2 cells were treated with roxadustat (Roxa) for 48hrs. Rabbit monoclonal anti- GAPDH (Anti-GAPDH: 2118S, Cell Signaling Technology) was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 50 μM, 4th, 8th, 12th lanes: Roxa 250 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-14 13h16m41s.scn and 1F T-cad.tif Western blot analysis of total cell lysates. UV-F2 cells were treated with daprodustat (Dapro) for 48hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 2 2. Number of cases/rows: 6 3. Variable List: * treatment: 1st, 3rd, 5th lanes from the left: control (without Dapro), 2nd, 4th, 6th lanes: Dapro 100 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-14 13h22m16s.scn and 1F atubulin.tif Western blot analysis of total cell lysates. UV-F2 cells were treated with daprodustat (Dapro) for 48hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 2 2. Number of cases/rows: 6 3. Variable List: * treatment: 1st, 3rd, 5th lanes from the left: control (without Dapro), 2nd, 4th, 6th lanes: Dapro 100 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-14 13h24m53s.scn and 1F GAPDH.tif Western blot analysis of total cell lysates. UV-F2 cells were treated with daprodustat (Dapro) for 48hrs. Anti-GAPDH was used as primary antibody. 1. Number of variables: 2 2. Number of cases/rows: 6 3. Variable List: * treatment: 1st, 3rd, 5th lanes from the left: control (without Dapro), 2nd, 4th, 6th lanes: Dapro 100 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2022-02-09 17h31m06s.scn and 2A T-cad.tif Western blot analysis of total cell lysates. UV-F2 cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without high molecular weight adiponectin (HMW-APN) (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2022-02-09 17h35m49s.scn and 2A atubulin.tif Western blot analysis of total cell lysates. UV-F2 cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without high molecular weight adiponectin (HMW-APN) (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2022-02-09 17h39m26s.scn and 2A APN.tif Western blot analysis of total cell lysates. UV-F2 cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without high molecular weight adiponectin (HMW-APN) (10 μg/mL) and Roxa (50 μM) for 48 hrs. Goat polyclonal anti-adiponectin (Anti-APN: AF1119, R&D Systems) was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-06-01 14h02m21s.scn and 2B Alix.tif Western blot analysis of extracellular vechicles (EVs) isolated from cell culture medium by differential ultracentrifugation. UV-F2 cells cultured in FBS-free Advanced DMEM were treated with or without HMW-APN (20 μg/mL) and Roxa (50 μM) for 48 hrs. Rabbit monoclonal anti-ALIX (Anti-Alix: ab186429, abcam) was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 20 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-06-01 14h05m20s.scn and 2B TSG101.tif Western blot analysis of extracellular vechicles (EVs) isolated from cell culture medium by differential ultracentrifugation. UV-F2 cells cultured in FBS-free Advanced DMEM were treated with or without HMW-APN (20 μg/mL) and Roxa (50 μM) for 48 hrs. Rabbit monoclonal anti-TSG101 (Anti-TSG101: ab125011, Abcam) was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 20 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-06-01 14h05m20s.scn and 2B TSG101.tif Western blot analysis of extracellular vechicles (EVs) isolated from cell culture medium by differential ultracentrifugation. UV-F2 cells cultured in FBS-free Advanced DMEM were treated with or without HMW-APN (20 μg/mL) and Roxa (50 μM) for 48 hrs. Rabbit polyclonal anti-syntenin (Anti-Syntenin: ab19903, Abcam) was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 20 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-06 13h58m50s.scn and 2C T-cad.tif Western blot analysis of total cell lysates. UV-F2 cells transfected control (Cont) or T-cadherin (T-cad) siRNA were cultured in DMEM containing 5% serum from adiponectin knockout mice with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-06 14h11m48s.scn and 2C atubulin.tif Western blot analysis of total cell lysates. UV-F2 cells transfected control (Cont) or T-cadherin (T-cad) siRNA were cultured in DMEM containing 5% serum from adiponectin knockout mice with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-06 14h14m54s.scn and 2C APN.tif Western blot analysis of total cell lysates. UV-F2 cells transfected control (Cont) or T-cadherin (T-cad) siRNA were cultured in DMEM containing 5% serum from adiponectin knockout mice with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-APN was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-15 13h27m46s.scn and 2D Alix.tif Western blot analysis of EVs isolated from cell culture medium. UV-F2 cells transfected Cont or T-cad siRNA were cultured in FBS-free Advanced DMEM with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-Alix was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-15 13h31m19s.scn and 2D TSG101.tif Western blot analysis of EVs isolated from cell culture medium. UV-F2 cells transfected Cont or T-cad siRNA were cultured in FBS-free Advanced DMEM with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-TSG101 was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-15 13h35m19s.scn and 2D Syntenin.tif Western blot analysis of EVs isolated from cell culture medium. UV-F2 cells transfected Cont or T-cad siRNA were cultured in FBS-free Advanced DMEM with HMW-APN (20 μg/mL) and with or without Roxa (50 μM) for 48 hrs. Anti-Syntenin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: T-cad siRNA, 4th, 8th, 12th lanes: T-cad siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2022-11-24 16h38m04s.scn and 3B T-cad.tif Western blot analysis of total cell lysates. F2T cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without HMW-APN (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2022-11-24 16h43m15s.scn and 3B atubulin.tif Western blot analysis of total cell lysates. F2T cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without HMW-APN (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2022-11-24 16h48m35s.scn and 3B APN.tif Western blot analysis of total cell lysates. F2T cells cultured in DMEM containing 5% serum from adiponectin knockout mice were treated with or without HMW-APN (10 μg/mL) and Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without HMW-APN or Roxa), 2nd, 6th, 10th lanes: Roxa 50 μM, 3rd, 7th, 11th lanes: HMW-APN 10 μg/mL, 4th, 8th, 12th lanes: HMW-APN and Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-10-13 13h40m01s.scn and 3D SYPRO Ruby.tif SYPRO Ruby staining in the cell lysates of F2T cells immunoprecipitated with Streptavidin SepharoseTM beads at 0, 0.5, 1, 2, and 4 hrs after biotinylation. UV-F2 cells were biotinylated after treated with or without Roxa for 40hrs. 1. Number of variables: 10 2. Number of cases/rows: 10 3. Variable List: * treatment: 1st lane from the left: at 0hr after biotinylation without Roxa, 2nd lane: at 0.5hr after biotinylation without Roxa, 3rd lane: at 1hr after biotinylation without Roxa, 4th lane: at 2hrs after biotinylation without Roxa, 5th lane: at 4hrs after biotinylation without Roxa, 6th lane: at 0hr after biotinylation with Roxa, 7th lane: at 0.5hr after biotinylation with Roxa, 8th lane: at 1hr after biotinylation with Roxa, 9th lane: at 2hrs after biotinylation with Roxa, 10th lane: at 4hrs after biotinylation with Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-10-12 14h02m05s.scn and 3D T-cad.tif Western blot analysis of cell lysates of UV-F2 cells immunoprecipitated with Streptavidin SepharoseTM beads at 0, 0.5, 1, 2, and 4 hrs after biotinylation. Anti-T-cad was used as primary antibody. 1. Number of variables: 10 2. Number of cases/rows: 10 3. Variable List: * treatment: 1st lane from the left: at 0hr after biotinylation without Roxa, 2nd lane: at 0.5hr after biotinylation without Roxa, 3rd lane: at 1hr after biotinylation without Roxa, 4th lane: at 2hrs after biotinylation without Roxa, 5th lane: at 4hrs after biotinylation without Roxa, 6th lane: at 0hr after biotinylation with Roxa, 7th lane: at 0.5hr after biotinylation with Roxa, 8th lane: at 1hr after biotinylation with Roxa, 9th lane: at 2hrs after biotinylation with Roxa, 10th lane: at 4hrs after biotinylation with Roxa. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-20 13h35m17s.scn and 4G T-cad.tif Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Adam12 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-07-20 13h38m46s.scn and 4G atubulin.tif Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Adam12 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-08-11 13h35m27s.scn and 4H Alix.tif Western blot analysis of EVs isolated from cell culture medium by differential ultracentrifugation. In the presence of HMW-APN (20 μg/mL), UV-F2 cells transfected control or Adam12 siRNA were cultured in FBS-free Advanced DMEM with or without Roxa (50 μM) for 48 hrs. Anti-Alix was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-08-11 13h39m01s.scn and 4H TSG101.tif Western blot analysis of EVs isolated from cell culture medium by differential ultracentrifugation. In the presence of HMW-APN (20 μg/mL), UV-F2 cells transfected control or Adam12 siRNA were cultured in FBS-free Advanced DMEM with or without Roxa (50 μM) for 48 hrs. Anti-TSG101 was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-08-11 13h42m07s.scn and 4H Syntenin.tif Western blot analysis of EVs isolated from cell culture medium by differential ultracentrifugation. In the presence of HMW-APN (20 μg/mL), UV-F2 cells transfected control or Adam12 siRNA were cultured in FBS-free Advanced DMEM with or without Roxa (50 μM) for 48 hrs. Anti-Syntenin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: Adam12 siRNA, 4th, 8th, 12th lanes: Adam12 siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-08-24 11h31m18s.scn and S1E T-cad.tif Western blot analysis of total cell lysates. HUVECs were treated with Roxa for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 100 μM, 4th, 8th, 12th lanes: Roxa 200 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-08-24 15h28m13s.scn and S1E atubulin.tif Western blot analysis of total cell lysates. HUVECs were treated with Roxa for 48 hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: control (without Roxa), 2nd, 6th, 10th lanes: Roxa 10 μM, 3rd, 7th, 11th lanes: Roxa 100 μM, 4th, 8th, 12th lanes: Roxa 200 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-22 13h39m35s.scn and S1H T-cad.tif Western blot analysis of total cell lysates of UV-F2 cells cultured under 21% or 5% oxygen for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 2 2. Number of cases/rows: 6 3. Variable List: * treatment: 1st, 3rd, 5th lanes from the left: under 21% oxygen, 2nd, 4th, 6th lanes: under 5% oxygen. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-03-22 13h43m40s.scn and S1H atubulin.tif Western blot analysis of total cell lysates of UV-F2 cells cultured under 21% or 5% oxygen for 48 hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 2 2. Number of cases/rows: 6 3. Variable List: * treatment: 1st, 3rd, 5th lanes from the left: under 21% oxygen, 2nd, 4th, 6th lanes: under 5% oxygen. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-06-09 15h35m45s.scn and S2B T-cad.tif Western blot analysis of total cell lysates. UV-F2 cells and those stably overexpressing syndecan-4 (sdc4) were treated with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Control (without Roxa), 2nd, 6th, 10th lanes: with Roxa 50 μM, 3rd, 7th, 11th lanes: overexpressing sdc4, 4th, 8th, 12th lanes: overexpressing sdc4 with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-06-09 15h39m49s.scn and S2B atubulin.tif Western blot analysis of total cell lysates. UV-F2 cells and those stably overexpressing syndecan-4 (sdc4) were treated with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Control (without Roxa), 2nd, 6th, 10th lanes: with Roxa 50 μM, 3rd, 7th, 11th lanes: overexpressing sdc4, 4th, 8th, 12th lanes: overexpressing sdc4 with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-05-26 16h04m39s.scn and S2C T-cad.tif Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Sdc4 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: sdc4 siRNA, 4th, 8th, 12th lanes: sdc4 siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: User 2023-05-26 16h09m52s.scn and S2C atubulin.tif Western blot analysis of total cell lysates. UV-F2 cells transfected Cont or Sdc4 siRNA were treated with or without Roxa (50 μM) for 48 hrs. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st, 5th, 9th lanes from the left: Cont siRNA, 2nd, 6th, 10th lanes: Cont siRNA with Roxa 50 μM, 3rd, 7th, 11th lanes: sdc4 siRNA, 4th, 8th, 12th lanes: sdc4 siRNA with Roxa 50 μM. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: F2_T-cad_2017-07-07 11h53m37s 11.477s.scn and S2D T-cad.tif Western blot analysis of total cell lysates of UV-F2 cells transfected control or Adam 12, 9, 10, 15, 17, or 19 siRNA. Anti-T-cad was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st-3rd lanes from the left: Control siRNA, 4th-6th lanes: Adam12 siRNA, 7th-9th lanes: Adam9 siRNA, 10th-12th lanes: Adam10 siRNA, 13th-15th lanes: Adam15 siRNA, 16th-18th lanes: Adam17 siRNA, 19th-21st lanes: Adam19 siRNA. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### DATA-SPECIFIC INFORMATION FOR: F2_Tub_2017-07-07 11h51m34s 13.609s.scn and S2D atubulin.tif Western blot analysis of total cell lysates of UV-F2 cells transfected control or Adam 12, 9, 10, 15, 17, or 19 siRNA. Anti-α-tubulin was used as primary antibody. 1. Number of variables: 4 2. Number of cases/rows: 12 3. Variable List: * treatment: 1st-3rd lanes from the left: Control siRNA, 4th-6th lanes: Adam12 siRNA, 7th-9th lanes: Adam9 siRNA, 10th-12th lanes: Adam10 siRNA, 13th-15th lanes: Adam15 siRNA, 16th-18th lanes: Adam17 siRNA, 19th-21st lanes: Adam19 siRNA. 1. Missing data codes: None 2. Specialized formats or other abbreviations used: None \######################################################################### Folder names of .scn (e.g. 1E) and file names of .tif (e.g. 1E atubulin) correspond to the figure number or supplementary figure number in paper, respectively. ## Sharing/Access information This is a section for linking to other ways to access the data, and for linking to sources the data is derived from, if any. Links to other publicly accessible locations of the data: None Data was derived from the following sources: None ## Code/Software The software used to run this submission is described above.